E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Severe alcoholic hepatitis |
|
MedDRA Classification |
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
To determine whether prednisolone or pentoxifylline improve the 28 day mortality (death rate) from severe alcoholic hepatitis. |
|
E.2.2 | Secondary objectives of the trial |
To determine the death rate from alcoholic hepatitis at 1 year following admission to hospital in patients treated with pentoxifylline or prednisolone To evaluate the economic cost of treating severe alcoholic hepatitis |
|
E.2.3 | Trial contains a sub-study | Yes |
E.2.3.1 | Full title, date and version of each sub-study and their related objectives |
A health economic evaluation, and an investigation into potential genetic causes of alcoholic hepatitis are incorporated into the main trial protocol. Three other analyses are incorporated into the body of the protocol; 1. A study into past prescribed medications will also take place in selected sites, to see if certain drugs/groups of drugs either trigger episodes of AH, or protect against them. 2. Inflammatory markers in serum - this will take place in all sites and will be used to see if it could be used to predict outcome. 3. Monocyte levels and function will be looked at in patients at selected sites, to see whether this explains why some patients develop systemic infections which contribute to renal failure and mortality. 4. Data will be collected from 200 patients (100 with alcoholic cirrhosis and 100 with cirrhosis due to viral hepatitis) from 4 centres involved with the main trial (Newcastle, Imperial, Nottingham and Glasgow) about health state utilities for each of the three main Child-Pugh classifications of cirrhosis. QOL tariffs generated using standard gamble methods will be compared to those derived from EQ-5D in order to validate or refute the use of the EQ-5D in the STOPAH population. STOPAH patients will not be eligible for this QOL study. The Trial Management Group intend to develop further nested sub-studies for which the STOPAH trial population would be eligible however these are still at a preliminary stage. |
|
E.3 | Principal inclusion criteria |
Aged 18 years or older Clinical Alcoholic Hepatitis: • Serum bilirubin > 80μmol/L • History of excess alcohol (> 80g/day male, > 60g/day female) to within 2 months of randomisation Less than 4 weeks since admission to hospital. Discriminant Function* greater than or equal to 32. Informed consent * DF = 4.6 x (Prothrombin time (PTPATIENT – PTCONTROL) + Serum Bilirubin (μmol/l) / 17.1, (PTCONTROL is defined as the mean value at each centre, this mean value may be updated on a weekly or monthly basis) |
|
E.4 | Principal exclusion criteria |
Abstinence of more than 2 months prior to randomisation Duration of clinically apparent jaundice > 3 months Other causes of liver disease including: o Evidence of chronic viral hepatitis (Hepatitis B or C), o Biliary obstruction, o Hepatocellular carcinoma Evidence of current malignancy (except non-melanotic skin cancer) Previous entry into the study, or use of either prednisolone or prednisolone within 6 weeks of admission. AST >500 U/L or ALT >300 U/L. (not compatible with alcoholic hepatitis) Patients with a serum creatinine greater than 500 μmol/L or requiring renal support. Patients dependent upon inotropic support (adrenaline or noradrenaline). Glypressin is allowed. Active gastro-intestinal haemorrhage Untreated sepsis Patients with known hypersensitivity to pentoxifylline, other methyl xanthines or any of the excipients Patients with cerebral haemmorrhage, extensive retinal haemorrhage, acute myocardial infarction or severe cardiac arrhythmias Pregnant or lactating women Patients with evidence of sepsis, gastrointestinal bleeding or renal failure may be treated for these conditions for up to 7 days and then re-screened. Once the condition has been stabilised these patients will be randomised using stratified randomisation procedures. Recent gastrointestinal bleeding: Gastrointestinal bleeding will be treated and the patient stabilised for at least 48 hours prior to screening and randomisation. Sepsis: All patients will be screened for infection as part of routine care. Positive culture and initiation of antibiotics with clinical or radiological signs of infection; as well as clinical suspicion will be recorded as sepsis. Patients with evidence of sepsis will be treated for a minimum of 2 days with appropriate antibiotics. Once the local principal investigator considers that the sepsis is under control then the patient may be rescreened and randomised. Renal Impairment: Patients who are oligo-anuric, have a creatinine > 500 uM/L or who require renal support will be given appropriate resuscitation therapy for up to 1 week. These patients may then be rescreened and considered for randomisation once they meet eligibility criteria. |
|
E.5 End points |
E.5.1 | Primary end point(s) |
Mortality rate at 28 days following start of treatment |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | No |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | Yes |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | Yes |
E.8.1.5 | Parallel group | No |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | Yes |
E.8.1.7.1 | Other trial design description |
|
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | Yes |
E.8.2.2 | Placebo | Yes |
E.8.2.3 | Other | No |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 60 |
E.8.5 | The trial involves multiple Member States | No |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.7 | Trial has a data monitoring committee | Yes |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
Last patient last visit (12 months after start of treatment of last patient entered into trial) |
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 4 |
E.8.9.1 | In the Member State concerned months | |
E.8.9.1 | In the Member State concerned days | |
E.8.9.2 | In all countries concerned by the trial years | 4 |
E.8.9.2 | In all countries concerned by the trial months | 0 |